| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Guest Access | Sign In via User Name/Password
|
|
|
|||||||
Guest Access | Sign In via User Name/Password |
|||||||||
* From Methodist Healthcare Memphis and the University of Tennessee (Dr. Wunderink), Memphis, TN; Joan XXIII University Hospital (Dr. Rello), University Rovira i Virgili, Tarragona, Spain; Pharmacia (Drs. Cammarata and Croos-Dabrera), Kalamazoo, MI; and Department of Internal Medicine, Pulmonary and Critical Care Division (Dr. Kollef), Washington University School of Medicine, St. Louis, MO.
Correspondence to: Richard G. Wunderink, MD, FCCP, Methodist Healthcare Memphis, 1265 Union Ave, Suite 501 Crews, Memphis, TN 38104-3499; e-mail: WunderiR{at}methodisthealth.org
Objective: To assess the effect of baseline variables, including treatment, on outcome in patients with nosocomial pneumonia due to methicillin-resistant Staphylococcus aureus (MRSA).
Design: Retrospective analysis of data from two prospective, randomized, double-blind studies.
Setting: Multinational study with 134 sites.
Patients: A total of 1,019 patients with suspected Gram-positive nosocomial pneumonia, including 339 patients with documented S aureus pneumonia (S aureus subset) and 160 patients with documented MRSA pneumonia (MRSA subset).
Interventions: Linezolid, 600 mg, or vancomycin, 1 g, q12h for 7 to 21 days, each with aztreonam.
Measurements and results: Outcome was measured by survival and clinical cure rates (assessed 12 to 28 days after the end of therapy). Logistic regression analysis was used to determine the effect of treatment and other baseline variables on outcome. Kaplan-Meier survival rates for linezolid vs vancomycin were 80.0% (60 of 75 patients) vs 63.5% (54 of 85 patients) for the MRSA subset (p = 0.03). Logistic regression analysis confirmed that the survival difference favoring linezolid remained significant after adjusting for baseline variables (odds ratio [OR], 2.2; 95% confidence interval [CI], 1.0 to 4.8; p = 0.05). Other baseline variables associated with significantly higher survival rates in MRSA pneumonia were serum creatinine levels less than or equal to two times the upper limit of normal and absence of cardiac comorbidities. Clinical cure rates for linezolid vs vancomycin (excluding indeterminate or missing outcomes) were 59.0% (36 of 61 patients) vs 35.5% (22 of 62 patients) for the MRSA subset (p < 0.01). Logistic regression analysis confirmed that the difference favoring linezolid remained significant after adjusting for baseline variables (OR, 3.3; 95% CI, 1.3 to 8.3; p = 0.01). Other baseline variables associated with significantly higher clinical cure rates in MRSA pneumonia were single-lobe pneumonia, absence of ventilator-associated pneumonia, and absence of oncologic and renal comorbidities.
Conclusions: In this retrospective analysis, initial therapy with linezolid was associated with significantly better survival and clinical cure rates than was vancomycin in patients with nosocomial pneumonia due to MRSA.
Key Words: linezolid • methicillin resistance • nosocomial pneumonia • regression analysis • Staphylococcus aureus • vancomycin
This article has been cited by other articles:
|
|
 |
|
  K. E. Kollef, R. M. Reichley, S. T. Micek, and M. H. Kollef The Modified APACHE II Score Outperforms Curb65 Pneumonia Severity Score as a Predictor of 30-Day Mortality in Patients With Methicillin-Resistant Staphylococcus aureus Pneumonia Chest, February 1, 2008; 133(2): 363 - 369. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Rello and J. Mallol Optimal Therapy for Methicillin-Resistant Staphylococcus aureus Pneumonia: What Is the Best Dosing Regimen? Chest, October 1, 2006; 130(4): 938 - 940. [Full Text] [PDF]
|
|
|
|
|
|
M. N. Jeffres, W. Isakow, J. A. Doherty, P. S. McKinnon, D. J. Ritchie, S. T. Micek, and M. H. Kollef Predictors of Mortality for Methicillin-Resistant Staphylococcus aureus Health-Care-Associated Pneumonia: Specific Evaluation of Vancomycin Pharmacokinetic Indices. Chest, October 1, 2006; 130(4): 947 - 955. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. McNicholas, A. Barber, G. Corbett-Feeney, and M. Cormican Linezolid audit: similarities and contrasts with published experience J. Antimicrob. Chemother., May 1, 2006; 57(5): 1008 - 1009. [Full Text] [PDF]
|
|
|
|
 |
|
 J D Hunter Ventilator associated pneumonia. Postgrad. Med. J., March 1, 2006; 82(965): 172 - 178. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. N. Jones, J. E. Ross, T. R. Fritsche, and H. S. Sader Oxazolidinone susceptibility patterns in 2004: report from the Zyvox(R) Annual Appraisal of Potency and Spectrum (ZAAPS) Program assessing isolates from 16 nations J. Antimicrob. Chemother., February 1, 2006; 57(2): 279 - 287. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. P. Howden, P. G. P. Charles, P. D. R. Johnson, P. B. Ward, M. L. Grayson, J. A. Weigelt, K. Itani, D. Stevens, W. Lau, M. Dryden, et al. Improved Outcomes with Linezolid for Methicillin-Resistant Staphylococcus aureus Infections: Better Drug or Reduced Vancomycin Susceptibility? Antimicrob. Agents Chemother., November 1, 2005; 49(11): 4816 - 4817. [Full Text] [PDF]
|
|
|
|
|
|
D. M. Livermore Tigecycline: what is it, and where should it be used? J. Antimicrob. Chemother., October 1, 2005; 56(4): 611 - 614. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. H. Kollef and S. T. Micek Staphylococcus Aureus Pneumonia: A "Superbug" Infection in Community and Hospital Settings Chest, September 1, 2005; 128(3): 1093 - 1097. [Full Text] [PDF]
|
|
|
|
|
|
C. A. DeRyke, T. P. Lodise Jr., M. J. Rybak, and P. S. McKinnon Epidemiology, Treatment, and Outcomes of Nosocomial Bacteremic Staphylococcus aureus Pneumonia Chest, September 1, 2005; 128(3): 1414 - 1422. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. H. Powers, D. Lin, D. Ross, R. Wunderink, M. Kollef, and J. Rello FDA Evaluation of Antimicrobials: Subgroup Analysis Chest, June 1, 2005; 127(6): 2298 - 2301. [Full Text] [PDF]
|
|
|
|
 |
|
 A. M. Cook Pharmacokinetic Alterations of Antimicrobials in the Critically Ill Journal of Pharmacy Practice, April 1, 2005; 18(2): 75 - 83. [Abstract] [PDF]
|
|
|
|
 |
|
 T. L. Mersfelder and C. L. Smith Linezolid pharmacokinetics in an obese patient Am. J. Health Syst. Pharm., March 1, 2005; 62(5): 464 - 467. [Full Text] [PDF]
|
|
|
|
 |
|
 Guidelines for the Management of Adults with Hospital-acquired, Ventilator-associated, and Healthcare-associated Pneumonia Am. J. Respir. Crit. Care Med., February 15, 2005; 171(4): 388 - 416. [Full Text] [PDF]
|
|
|
|
|
|
S. A. Voils, K. S. Kim, and E. T. Wittbrodt Recent Trends in the Management of Ventilator-Associated Pneumonia Journal of Pharmacy Practice, February 1, 2005; 18(1): 53 - 62. [Abstract] [PDF]
|
|
|
|
|
|
A. Combes, C.-E. Luyt, J.-Y. Fagon, M. Wollf, J.-L. Trouillet, C. Gibert, and J. Chastre Impact of Methicillin Resistance on Outcome of Staphylococcus aureus Ventilator-associated Pneumonia Am. J. Respir. Crit. Care Med., October 1, 2004; 170(7): 786 - 792. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. C. Kalil, S. E. Puumala, and J. Stoner Unresolved Questions With the Use of Linezolid vs Vancomycin for Nosocomial Pneumonia Chest, June 1, 2004; 125(6): 2370 - 2371. [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
